ApoGen Biotechnologies, a biotechnology firm engaged in the development of a new class of therapeutics targeting drivers of cancer genomic mutations, has expanded its series A financing to a total of $11m.
The Centre for the Commercialization of Antibodies and Biologics (CCAB) has agreed to provide a new investment to help advance ImmunoBiochem’s novel breast cancer therapeutic candidate one step closer to the clinic.
Harbour BioMed and Sichuan Kelun-Biotech Biopharmaceutical (Kelun-Biotech) have entered into a partnership to develop and commercialize the latter’s A167, an anti-PD-L1 antibody, for the treatment of cancer.
AbbVie has entered into clinical research collaboration with Tolero Pharmaceuticals to assess the potential benefits of venetoclax and alvocidib combination in relapsed/refractory acute myeloid leukemia (AML).
WuXi AppTec ‘s research service division and Cyclica have announced a multi-phase collaboration to advance drug discovery programs by driving insights into small molecule polypharmacology, while further evolving Cyclica’s biophysics and AI-augmented platform.
Biotechnology firm BioNTech has collaborated with Pfizer for the development of mRNA-based vaccines to prevent influenza (flu).
Haplogen and German pharma firm Bayer have entered into a collaboration to develop drug candidates for the treatment of chronic obstructive pulmonary disease (COPD) and other pulmonary diseases.
Orchard Therapeutics, a biotechnology company focused on developing gene therapies for rare diseases, has raised $150m through a Series C funding round.
Canadian specialty pharmaceutical firm Aralez Pharmaceuticals has entered into two separate agreements to sell substantially all of its assets for a total of $250m.
Clinical-stage biotechnology firm Therachon has raised $60m mezzanine financing to advance lead program in achondroplasia and expand rare disease pipeline.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.